CELCUITY INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.09 USD | -1.20% |
|
-7.70% | +24.16% |
| Mar. 29 | Celcuity Inc. Enters into Second Amendment to its Existing Loan and Security Agreement | CI |
| Mar. 28 | Craig Hallum Adjusts Celcuity Price Target to $25 From $20, Maintains Buy Rating | MT |
Financials (USD)
| Sales 2024 * | 5.04M | Sales 2025 * | 11.71M | Capitalization | 558M |
|---|---|---|---|---|---|
| Net income 2024 * | -86M | Net income 2025 * | -127M | EV / Sales 2024 * | 111 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 47.6 x |
| P/E ratio 2024 * |
-6.33
x | P/E ratio 2025 * |
-5.28
x | Employees | 55 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.63% |
More Fundamentals
* Assessed data
More news
Latest transcript on Celcuity Inc.
More recommendations
More press releases
| 1 day | -2.16% | ||
| 1 week | -7.81% | ||
| Current month | -16.34% | ||
| 1 month | +1.80% | ||
| 3 months | +24.62% | ||
| 6 months | +72.10% | ||
| Current year | +24.02% |
1 week
18.00
20.15
1 month
17.2522.19
Current year
13.4822.19
1 year
8.3922.19
3 years
4.8133.01
5 years
4.0333.01
10 years
4.0333.01
| Managers | Title | Age | Since |
|---|---|---|---|
Lance Laing
FOU | Founder | 62 | 11-12-31 |
Brian Sullivan
CEO | Chief Executive Officer | 62 | 11-12-31 |
Vicky Hahne
DFI | Director of Finance/CFO | 57 | 17-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Brian Sullivan
CEO | Chief Executive Officer | 62 | 11-12-31 |
Richard Nigon
BRD | Director/Board Member | 76 | 16-12-31 |
David Dalvey
BRD | Director/Board Member | 65 | 14-01-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.25% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-15 | 18.09 | -1.20% | 107,808 |
| 24-04-12 | 18.31 | -7.01% | 240,726 |
| 24-04-11 | 19.69 | +1.60% | 66,321 |
| 24-04-10 | 19.38 | -2.61% | 138,630 |
| 24-04-09 | 19.9 | +1.53% | 169,640 |
Delayed Quote Nasdaq, April 15, 2024 at 03:24 pm EDT
More quotes
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small molecule reversible inhibitor, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic target of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its initial clinical development programs for gedatolisib are focusing on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. Its VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells to identify new groups of cancer patients.
Calendar
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
18.31
USD
Average target price
29.5
USD
Spread / Average Target
+61.11%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +24.02% | 558M | |
| -2.02% | 102B | |
| +2.12% | 97.22B | |
| +4.22% | 22.27B | |
| -15.89% | 20.84B | |
| -4.50% | 19.19B | |
| -41.75% | 16.76B | |
| -23.79% | 14.76B | |
| +0.20% | 13.54B | |
| +22.54% | 11.53B |
- Stock Market
- Equities
- CELC Stock
